Concepts (57)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Neoplasms, Germ Cell and Embryonal | 1 | 2016 | 11 | 0.540 |
Why?
|
| Huntington Disease | 1 | 2016 | 15 | 0.540 |
Why?
|
| Brain Neoplasms | 2 | 2018 | 638 | 0.460 |
Why?
|
| Breast Neoplasms | 3 | 2020 | 761 | 0.290 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2020 | 192 | 0.170 |
Why?
|
| Anthracyclines | 1 | 2020 | 62 | 0.170 |
Why?
|
| Radiodermatitis | 1 | 2018 | 6 | 0.160 |
Why?
|
| Hypoglycemic Agents | 1 | 2018 | 181 | 0.150 |
Why?
|
| C-Reactive Protein | 1 | 2018 | 239 | 0.150 |
Why?
|
| Stroke Volume | 1 | 2020 | 349 | 0.140 |
Why?
|
| Carcinoma, Papillary | 1 | 2016 | 14 | 0.140 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 1 | 2016 | 53 | 0.130 |
Why?
|
| Neoadjuvant Therapy | 1 | 2016 | 67 | 0.130 |
Why?
|
| Corpus Striatum | 1 | 2016 | 60 | 0.130 |
Why?
|
| Inflammation | 1 | 2018 | 540 | 0.120 |
Why?
|
| Cardiovascular Diseases | 1 | 2020 | 1125 | 0.100 |
Why?
|
| Child | 1 | 2016 | 2441 | 0.080 |
Why?
|
| Radiotherapy | 2 | 2018 | 82 | 0.070 |
Why?
|
| Humans | 6 | 2020 | 32024 | 0.070 |
Why?
|
| Histone Deacetylase Inhibitors | 1 | 2003 | 21 | 0.050 |
Why?
|
| Enzyme Inhibitors | 1 | 2003 | 165 | 0.050 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2003 | 148 | 0.050 |
Why?
|
| Male | 2 | 2018 | 19195 | 0.050 |
Why?
|
| Female | 5 | 2020 | 19953 | 0.050 |
Why?
|
| Middle Aged | 3 | 2020 | 11868 | 0.050 |
Why?
|
| Aged, 80 and over | 2 | 2018 | 4000 | 0.050 |
Why?
|
| Aged | 3 | 2018 | 10340 | 0.040 |
Why?
|
| Receptor, erbB-2 | 1 | 2020 | 65 | 0.040 |
Why?
|
| Radiotherapy, Conformal | 1 | 2018 | 19 | 0.040 |
Why?
|
| Maximum Tolerated Dose | 1 | 2018 | 61 | 0.040 |
Why?
|
| Lymphatic Metastasis | 1 | 2018 | 170 | 0.040 |
Why?
|
| Skin | 1 | 2018 | 210 | 0.030 |
Why?
|
| SEER Program | 1 | 2016 | 35 | 0.030 |
Why?
|
| Mastectomy, Segmental | 1 | 2016 | 27 | 0.030 |
Why?
|
| Survival Rate | 1 | 2018 | 885 | 0.030 |
Why?
|
| Lymph Node Excision | 1 | 2016 | 90 | 0.030 |
Why?
|
| Ethnic Groups | 1 | 2018 | 476 | 0.030 |
Why?
|
| Adult | 2 | 2018 | 9366 | 0.030 |
Why?
|
| Prognosis | 1 | 2018 | 1505 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2016 | 757 | 0.030 |
Why?
|
| Follow-Up Studies | 1 | 2018 | 2280 | 0.030 |
Why?
|
| Risk Factors | 1 | 2020 | 3869 | 0.030 |
Why?
|
| European Continental Ancestry Group | 1 | 2016 | 1169 | 0.020 |
Why?
|
| Young Adult | 1 | 2018 | 2615 | 0.020 |
Why?
|
| African Americans | 1 | 2016 | 1428 | 0.020 |
Why?
|
| Mice, Inbred MRL lpr | 1 | 2003 | 3 | 0.010 |
Why?
|
| Hydroxamic Acids | 1 | 2003 | 21 | 0.010 |
Why?
|
| Interleukin-10 | 1 | 2003 | 30 | 0.010 |
Why?
|
| Interleukin-12 | 1 | 2003 | 29 | 0.010 |
Why?
|
| Interferon-gamma | 1 | 2003 | 57 | 0.010 |
Why?
|
| Autoantibodies | 1 | 2003 | 49 | 0.010 |
Why?
|
| Down-Regulation | 1 | 2003 | 142 | 0.010 |
Why?
|
| Interleukin-6 | 1 | 2003 | 253 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2003 | 508 | 0.010 |
Why?
|
| Kidney | 1 | 2003 | 515 | 0.010 |
Why?
|
| Mice | 1 | 2003 | 2475 | 0.010 |
Why?
|
| Animals | 1 | 2003 | 7466 | 0.010 |
Why?
|